Ethris’ proprietary lipidoid formulation has a unique composition and stabilization mix that allows excellent mRNA stability at temperatures ranging from -20°C to room temperature. Ethris has additionally developed lyophilisation and rapid rehydration processes providing product stability for long-term storage and distribution at room temperature.

The proprietary lipidoid formulation, in combination with an optimized nebulisation technology ensures delivery of potent, high quality and maximum integrity LNP aerosols into the respiratory tract with short application times.

Ethris’ SNaP technology is based on its proprietary library of lipidoid compounds and offers significant advantages:

1. Potent localised delivery
2. Superior mechanical and thermo-stability
3. Scalable lyophilisation
4. Best-in-class nebulisation for inhaled delivery
5. Versatile routes of administration and cargoes

More information about this asset can be found